Which countries run stem-cell trials for Lupus (SLE)?
Sampled registrations place sites in 10 countries. United States is the largest single contributor at roughly 42% of country mentions. Snapshot 2026-08-29.
Country distribution
| Country | Studies with a site there |
|---|---|
| United States | 17 |
| China | 11 |
| South Korea | 3 |
| France | 2 |
| Brazil | 2 |
| Belarus | 1 |
| Spain | 1 |
| Germany | 1 |
| Pakistan | 1 |
| United Kingdom | 1 |
A study with sites in several countries is counted once per country, taken from the location block of each registry record.
What the map means for Lupus (SLE)
Immune-reset work concentrates in a small number of academic haematology and rheumatology centres, notably in Europe, China and the US. Intravenous mesenchymal offers marketed to lupus patients internationally sit far outside that group.
Where recruitment is actually open
| Country | Open studies with a site there |
|---|---|
| China | 2 |
| United States | 2 |
| Spain | 1 |
What travelling for a trial actually involves
If a site is abroad, the practical questions are who provides follow-up at home, what happens if an adverse event occurs after you fly back, and whether the protocol permits remote assessment at all. Most do not.
Multi-country studies, named
Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.
No sampled study for this condition lists sites in more than one country, so the research base here is made of single-centre work rather than multinational collaboration.
Why trial geography is not a shortlist
Trial locations follow regulation, funding and sponsor headquarters, not clinical quality. Countries with clear conditional pathways for advanced therapies and large public research budgets register more studies. A country appearing here also says nothing about whether commercial clinics there operate under the same oversight as the registered trials.
Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.
When these studies started
Registrations by start year since 2020: 2021 (1), 2022 (2), 2023 (2), 2024 (1), 2025 (4), 2026 (1). Activity for this condition spans 2000 to 2026, which shows whether interest is growing, flat or past its peak.
Frequently asked
Which countries run stem-cell trials for Lupus (SLE)?
Sites are registered in 10 countries; the largest is United States (~42% of country mentions, 2026-08-29).
Does a country with many trials mean better treatment there?
No — trial counts describe where research is permitted and paid for. Care quality is decided at the level of the individual provider and product.
Are trial sites and commercial clinics the same thing?
Usually not. The hospital running a registered study is often unrelated to clinics marketing treatments to international patients in the same city.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.